Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. T. Schermuly, E. Dony, H. A. Ghofrani, S. Pullamsetti, R. Savai, N. Weissmann, W. Seeger, F. Grimminger (Giessen, Germany). Tyrosine kinase inhibition in pulmonary hypertension: the anti-proliferative approach. Eur Respir J 2006; 28: Suppl. 50, 985

Member's Comments

No comment yet.

Related content which might interest you: Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Eur Respir Rev 2008; 17: 72-73 Year: 2008 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension Source: Annual Congress 2005 - Scientific year in review Year: 2005 Novel treatment for pulmonary vascular disease: lessons from pathophysiology Source: Annual Congress 2006 - Molecular pathology: an approach to lung diseases Year: 2006 Pulmonary hypertension in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 892-905 Year: 2003 The burden of pulmonary hypertension Source: Annual Congress 2006 - The burden of pulmonary hypertension Year: 2006 Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target Source: Eur Respir J 2011; 38: 1453-1460 Year: 2011 Role of anti-proliferative therapy in PAH Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006 PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Update on current treatment options of pulmonary hypertension Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine Year: 2006 Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Pulmonary hypertension in COPD Source: Eur Respir J 2008; 32: 1371-1385 Year: 2008 Pulmonary hypertension: the science behind the disease spectrum Source: Eur Respir Rev 2012; 21: 19-26 Year: 2012